Multiple sclerosis: two blood markers associated with the risk of worsening

Combining two blood markers could help identify some people at greater risk of their multiple sclerosis worsening. An analysis drawing on three clinical trials links B cells and neurofilament light chains to the course of the disease. But these findings, available here only as a PubMed abstract, are not enough to establish a test for choosing or adjusting treatment.

Illustration of B cells and a blood sample for the study of multiple sclerosis biomarkers.
Gadgets & TechEditorial illustration, not study data.

An analysis based on three clinical trials

The researchers studied 15,025 blood samples from 2,370 people enrolled in the phase III OPERA I, OPERA II and ORATORIO trials. These participants had relapsing or primary progressive multiple sclerosis. The analysis examined B-cell populations before and during treatment, and their relationships with the course of the disease.

Ocrelizumab, a treatment targeting B cells carrying CD20, reduced the different circulating B-cell populations. This reduction was greater with increasing drug exposure and treatment duration. The abstract does not specify the exact follow-up period used for each analysis.

Two markers associated with a less favorable course

In people with relapsing disease, the persistence of certain detectable B-cell populations during treatment was associated with more new or enlarging lesions on MRI. However, this association does not demonstrate that intensifying B-cell depletion would necessarily improve clinical outcomes.

Among participants treated with interferon beta-1a, high baseline B-cell levels combined with high serum neurofilament light chain levels identified a group with greater disability progression. The reported hazard ratio was 3.10. The abstract provides neither the corresponding absolute risk nor its confidence interval.

In this subgroup, ocrelizumab was associated with less disability progression than the comparator treatment, with a hazard ratio of 0.25. This subgroup finding is not a promise for any individual and cannot be used to calculate how many people would avoid worsening.

A signal for research, not a treatment rule

The value of this analysis lies in bringing together a cellular marker, B cells, and a blood marker linked to nerve damage, neurofilament light chains. Their combination could help better characterize the risk of progression in certain relapsing forms.

The key limitation concerns clinical use: the abstract does not describe a trial in which treatment was chosen or adjusted based on this combination of markers. It therefore establishes neither a validated personalized strategy nor a depletion target to aim for. Findings concerning relapsing forms should not automatically be extrapolated to primary progressive forms either.

Limitations to keep in mind

Only the PubMed abstract was consulted. Detailed thresholds, absolute risks, confidence intervals, the handling of multiple analyses and safety data are not available in the source material. Funding and conflicts of interest have not been verified.

What we can take away

The B-cell–neurofilament combination is a potential avenue for risk stratification, not yet a validated method for guiding treatment.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.